{"transactions":[{"id":2727382,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-05T20:31:37.000Z","date":"2021-05-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":163609,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-21-018358","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321018358/doc4.xml","form_type":"4"}},{"id":2727381,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:31:37.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":2500,"price":26.6409,"value":66602.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $27.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-21-018358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321018358/doc4.xml","form_type":"4"}},{"id":2727380,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-05-05T20:31:37.000Z","date":"2021-05-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0000899243-21-018358","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321018358/doc4.xml","form_type":"4"}},{"id":2754377,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-07T21:17:22.000Z","date":"2021-04-05","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":166109,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-21-015309","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015309/doc4.xml","form_type":"4"}},{"id":2754376,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-07T21:17:22.000Z","date":"2021-04-05","kind":"sale","acquired":false,"shares":2500,"price":25.539,"value":63847.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.165 to $26.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-21-015309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015309/doc4.xml","form_type":"4"}},{"id":2754375,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-04-07T21:17:22.000Z","date":"2021-04-05","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0000899243-21-015309","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321015309/doc4.xml","form_type":"4"}},{"id":2809017,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-03-04T22:52:42.000Z","date":"2021-03-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":168609,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-21-009904","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321009904/doc4.xml","form_type":"4"}},{"id":2809016,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-04T22:52:42.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":884,"price":26.5651,"value":23483.5484,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $26.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-21-009904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321009904/doc4.xml","form_type":"4"}},{"id":2809015,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-04T22:52:42.000Z","date":"2021-03-03","kind":"sale","acquired":false,"shares":1616,"price":25.8529,"value":41778.2864,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.355 to $26.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4084,"source":{"system":"sec-edgar","filing":"0000899243-21-009904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321009904/doc4.xml","form_type":"4"}},{"id":2809014,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-03-04T22:52:42.000Z","date":"2021-03-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0000899243-21-009904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321009904/doc4.xml","form_type":"4"}},{"id":2846342,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-20T00:01:03.000Z","date":"2021-02-17","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":75000,"derivative":{"exercise_price":28.69,"expiration_date":"2031-02-16","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-21-007445","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321007445/doc4.xml","form_type":"4"}},{"id":2879237,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-04T22:47:33.000Z","date":"2021-02-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":171109,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-21-004959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321004959/doc4.xml","form_type":"4"}},{"id":2879236,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-04T22:47:33.000Z","date":"2021-02-03","kind":"sale","acquired":false,"shares":2500,"price":25.35,"value":63375.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-21-004959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321004959/doc4.xml","form_type":"4"}},{"id":2879235,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-02-04T22:47:33.000Z","date":"2021-02-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0000899243-21-004959","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321004959/doc4.xml","form_type":"4"}},{"id":2915927,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T23:27:53.000Z","date":"2021-01-04","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":173609,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-21-000743","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321000743/doc4.xml","form_type":"4"}},{"id":2915926,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T23:27:53.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":537,"price":31.7775,"value":17064.5175,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.72 to $32.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-21-000743","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321000743/doc4.xml","form_type":"4"}},{"id":2915925,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T23:27:53.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":1963,"price":31.3093,"value":61460.1559,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.72 to $31.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3737,"source":{"system":"sec-edgar","filing":"0000899243-21-000743","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321000743/doc4.xml","form_type":"4"}},{"id":2915924,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T23:27:53.000Z","date":"2021-01-04","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":5700,"source":{"system":"sec-edgar","filing":"0000899243-21-000743","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924321000743/doc4.xml","form_type":"4"}},{"id":2942740,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-17T00:42:08.000Z","date":"2020-12-15","kind":"exercise","acquired":false,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":176109,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0000899243-20-034189","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320034189/doc4.xml","form_type":"4"}},{"id":2942739,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-17T00:42:08.000Z","date":"2020-12-15","kind":"exercise","acquired":true,"shares":3200,"price":10.86,"value":34752.0,"ownership":{"direct":true},"balance_after":3200,"source":{"system":"sec-edgar","filing":"0000899243-20-034189","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320034189/doc4.xml","form_type":"4"}},{"id":2956673,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-04T21:34:31.000Z","date":"2020-12-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":179309,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-032759","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320032759/doc4.xml","form_type":"4"}},{"id":2956672,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T21:34:31.000Z","date":"2020-12-03","kind":"sale","acquired":false,"shares":2500,"price":32.4221,"value":81055.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.985 to $32.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-032759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320032759/doc4.xml","form_type":"4"}},{"id":2956671,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-12-04T21:34:31.000Z","date":"2020-12-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000899243-20-032759","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320032759/doc4.xml","form_type":"4"}},{"id":2981423,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-13T21:26:07.000Z","date":"2020-11-11","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":181809,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-20-030997","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030997/doc4.xml","form_type":"4"}},{"id":2981422,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-13T21:26:07.000Z","date":"2020-11-11","kind":"sale","acquired":false,"shares":5000,"price":34.9,"value":174500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-030997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030997/doc4.xml","form_type":"4"}},{"id":2981421,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-13T21:26:07.000Z","date":"2020-11-11","kind":"exercise","acquired":true,"shares":5000,"price":10.86,"value":54300.0,"ownership":{"direct":true},"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000899243-20-030997","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030997/doc4.xml","form_type":"4"}},{"id":2992897,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-11-05T01:37:20.000Z","date":"2020-11-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":186809,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-030419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030419/doc4.xml","form_type":"4"}},{"id":2992896,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:37:20.000Z","date":"2020-11-03","kind":"sale","acquired":false,"shares":2500,"price":31.9492,"value":79873.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.60 to $32.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-030419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030419/doc4.xml","form_type":"4"}},{"id":2992895,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-11-05T01:37:20.000Z","date":"2020-11-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000899243-20-030419","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320030419/doc4.xml","form_type":"4"}},{"id":3010934,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-10-07T20:27:21.000Z","date":"2020-10-05","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":189309,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-027717","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027717/doc4.xml","form_type":"4"}},{"id":3010933,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-07T20:27:21.000Z","date":"2020-10-05","kind":"sale","acquired":false,"shares":227,"price":31.985,"value":7260.595,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.75 to $32.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-027717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027717/doc4.xml","form_type":"4"}},{"id":3010932,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-07T20:27:21.000Z","date":"2020-10-05","kind":"sale","acquired":false,"shares":2273,"price":31.2042,"value":70927.1466,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.74 to $31.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":227,"source":{"system":"sec-edgar","filing":"0000899243-20-027717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027717/doc4.xml","form_type":"4"}},{"id":3010931,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-10-07T20:27:21.000Z","date":"2020-10-05","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000899243-20-027717","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320027717/doc4.xml","form_type":"4"}},{"id":3037806,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-04T21:27:05.000Z","date":"2020-09-03","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":191809,"derivative":{"exercise_price":10.86,"expiration_date":"2029-09-08","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0000899243-20-024374","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320024374/doc4.xml","form_type":"4"}},{"id":3037805,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-09-04T21:27:05.000Z","date":"2020-09-03","kind":"sale","acquired":false,"shares":2358,"price":29.6338,"value":69876.5004,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.035 to $30.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-20-024374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320024374/doc4.xml","form_type":"4"}},{"id":3037804,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-09-04T21:27:05.000Z","date":"2020-09-03","kind":"sale","acquired":false,"shares":142,"price":28.95,"value":4110.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020."}],"balance_after":2358,"source":{"system":"sec-edgar","filing":"0000899243-20-024374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320024374/doc4.xml","form_type":"4"}},{"id":3037803,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2020-09-04T21:27:05.000Z","date":"2020-09-03","kind":"exercise","acquired":true,"shares":2500,"price":10.86,"value":27150.0,"ownership":{"direct":true},"balance_after":2500,"source":{"system":"sec-edgar","filing":"0000899243-20-024374","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320024374/doc4.xml","form_type":"4"}},{"id":3296754,"issuer":{"id":6669,"kind":"organization","name":"Black Diamond Therapeutics, Inc.","symbol":"BDTX"},"owners":[{"id":139703,"kind":"person","name":"Roberts Christopher D.","position":1,"cik":"0001788368","reported_name":"Roberts Christopher D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-31T21:52:39.000Z","date":"2020-01-29","kind":"grant","acquired":true,"shares":54711,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of this option shall vest and become exercisable on February 3, 2021, with the remainder vesting in 36 equal monthly installments thereafter."}],"balance_after":54711,"derivative":{"exercise_price":19,"expiration_date":"2030-01-29","underlying":"Common Stock","underlying_shares":54711},"source":{"system":"sec-edgar","filing":"0000899243-20-002444","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701541/000089924320002444/doc4.xml","form_type":"4"}}]}